Beijing Hanmi Pharmaceutical Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jun 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for N-benzoate group substituted benzopyrroline-2-one derivative and use thereof (US 10,322,108) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Anti-PD-L1/anti-CD47 bispecific antibody (US 11,739,151) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same (US 11,753,471) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof (US 11,827,697) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for IRAK4 inhibitor and use thereof (US 10,562,902) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,453,062 | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,789,202 | Method for treating cancer using an interferon alpha conjugate In force · From the USPTO record | In force | From the USPTO record | |
| US 9,840,517 | Compound inhibiting activities of BTK and/or JAK3 kinases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,273,242 | Compound Inhibiting Activities of BTK And/Or JAK3 Kinases In force · Medium confidence | In force | Medium confidence | |
| US 10,322,108 | N-benzoate group substituted benzopyrroline-2-one derivative and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,562,902 | IRAK4 inhibitor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,988,482 | IRAK4 inhibitor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,319,378 | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,498,977 | Heterodimeric Immunoglobulin Constructs and Preparation Methods Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,753,471 | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 2 no status recorded